Halle Moore, MD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses the impact of the Phase III POSITIVE (NCT02308085) results, which demonstrated that for young women with early HR-positive breast desiring pregnancy, temporary interruption of endocrine therapy to attempt pregnancy does not confer a greater short-term risk of recurrence than that observed in a modern historical control group that did not interrupt endocrine therapy. These results provide prospective evidence-based guidance for young patients and reassurance to those who wish to become pregnant. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.